# Eptinezumab as Preventive Treatment of Migraine in Adults With Migraine

> **NCT04921384** · PHASE3 · COMPLETED · sponsor: **H. Lundbeck A/S** · enrollment: 981 (actual)

## Conditions studied

- Migraine

## Interventions

- **DRUG:** Placebo
- **DRUG:** Eptinezumab

## Key facts

- **NCT ID:** NCT04921384
- **Lead sponsor:** H. Lundbeck A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-29
- **Primary completion:** 2024-10-01
- **Final completion:** 2025-02-17
- **Target enrollment:** 981 (ACTUAL)
- **Last updated:** 2026-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04921384

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04921384, "Eptinezumab as Preventive Treatment of Migraine in Adults With Migraine". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04921384. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*